UTHR
Earnings in 3 days · May 6, 2026 · Before open
Signal
Leaning Bullish1
Price
1
Move-0.17%Quiet session
Volume
1
Volume0.4× avgLight volume
Technical
1
RSIRSI 57Momentum positive
PRICE
Prev Close
571.35
Open
569.00
Day Range565.56 – 573.30
565.56
573.30
52W Range272.12 – 607.89
272.12
607.89
89% of range
VOLUME & SIZE
Avg Volume
525.3K
FUNDAMENTALS
P/E Ratio
20.5x
EPS (TTM)
Div Yield
No dividend
Beta
0.44
Low vol
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +11% YoY · 88% gross margin
Valuation
FAIR
P/E 20x vs ~20x sector
Health
STRONG
CR 6.6 · FCF $23.49/sh
Strong Buy
Key MetricsTTM
Market Cap$25.00B
Revenue TTM$3.18B
Net Income TTM$1.33B
Free Cash Flow$1.04B
Gross Margin87.9%
Net Margin41.9%
Operating Margin46.9%
Return on Equity19.3%
Return on Assets16.9%
Debt / Equity0.00
Current Ratio6.60
EPS TTM$30.13

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
6 strong
81/100
Liquidity
6.60Strong
Leverage
0.00Strong
Coverage
76.5xStrong
ROE
19.3%Strong
ROIC
15.9%Strong
Cash
$1.6BStrong
ANALYST COVERAGE29 analysts
BUY
+7.4%upside to target
L $519.00
Med $612.50consensus
H $700.00
Buy
1655%
Hold
1241%
Sell
13%
16 Buy (55%)12 Hold (41%)1 Sell (4%)
Full report →
Stock Health
Composite Score
4 of 4 signals bullish
10/10
Technicals
RSI RangeRSI 57 — Bullish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 6.60 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
PDividend PaymentAug 10, 2026
In 99 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 17.8%

+14.5% vs SMA 50 · +34.9% vs SMA 200

Momentum

RSI57.2
Positive momentum, not extended
MACD+14.09
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$607.9+6.6%
Current
$570.4
EMA 50
$508.0-10.9%
EMA 200
$424.0-25.7%
52W Low
$272.1-52.3%
52-Week RangeNear 52-week high
$272.189th %ile$607.9
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 12 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$3.2B
$3.2B$3.3B
$27.48
±4%
High11
FY2026(current)
$3.3B
$3.2B$3.4B
+2.5%$29.37+6.9%
±8%
High12
FY2027
$3.8B
$3.3B$4.4B
+14.4%$33.96+15.6%
±23%
High11
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryUTHR
Last 8Q
+0.2%avg beat
Beat 4 of 8 quartersMissed 4 Estimates rising
+9%
Q2'24
-9%
Q3'24
-1%
Q4'24
-3%
Q1'25
+5%
Q2'25
-12%
Q3'25
+4%
Q4'25
+8%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →
No recent activity
Morgan StanleyOverweight → Equal-Weight
Jul 11
DOWNGRADE
Goldman SachsSell → Neutral
Feb 12
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $51.6M sold · 30d window
Rothblatt Martine ADir
$205K
Apr 30
SELL
Rothblatt Martine ADir
$681K
Apr 30
SELL
Rothblatt Martine ADir
$2.2M
Apr 30
SELL
Rothblatt Martine ADir
$939K
Apr 30
SELL
Rothblatt Martine ADir
$533K
Apr 30
SELL
Rothblatt Martine ADir
$179K
Apr 30
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Swedbank AB
327K
2
Pictet Asset Management Holding SA
309K
3
Nuveen, LLC
191K
4
FIFTH THIRD BANCORP
165K
5
Robeco Institutional Asset Management B.V.
128K
6
HSBC HOLDINGS PLC
119K
7
THRIVENT FINANCIAL FOR LUTHERANS
106K
8
Retirement Systems of Alabama
98K
News & Activity

UTHR News

20 articles · 4h ago

About

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Martine Rothblatt
Country
United States
Gil GoldenSenior Vice President & Chief Medical Officer
Paul A. MahonExecutive Vice President, General Counsel & Corporate Secretary
Leigh PetersonExecutive Vice President of Product Development & Xenotransplantation